Assessment of the EarlyCDT-Lung test as an early biomarker of lung cancer in ever-smokers: A retrospective nested case-control study in two prospective cohorts

Research output: Contribution to journal › Journal article › Research › peer-review

Documents

  • Fulltext

    Final published version, 731 KB, PDF document

  • Wendy Yi-Ying Wu
  • Zahra Haider
  • Xiaoshuang Feng
  • Alicia K. Heath
  • Antonio Agudo
  • Giovanna Masala
  • Hilary A. Robbins
  • Maria-Jose Huerta
  • Marcela Guevara
  • Matthias B. Schulze
  • Miguel Rodriguez-Barranco
  • Paolo Vineis
  • Rosario Tumino
  • Rudolf Kaaks
  • Renee T. Fortner
  • Sabina Sieri
  • Salvatore Panico
  • Therese Haugdahl Nost
  • Torkjel M. Sandanger
  • Tonje Braaten
  • Mattias Johansson
  • Beatrice Melin
  • Mikael Johansson

The EarlyCDT-Lung test is a blood-based autoantibody assay intended to identify high-risk individuals for low-dose computed tomography lung cancer screening. However, there is a paucity of evidence on the performance of the EarlyCDT-Lung test in ever-smokers. We conducted a nested case-control study within two prospective cohorts to evaluate the risk-discriminatory performance of the EarlyCDT-Lung test using prediagnostic blood samples from 154 future lung cancer cases and 154 matched controls. Cases were selected from those who had ever smoked and had a prediagnostic blood sample

Original languageEnglish
JournalInternational Journal of Cancer
Volume159
Issue number9
Pages (from-to)2002-2010
Number of pages9
ISSN0020-7136
DOIs
Publication statusPublished - 2023

    Research areas

  • biomarkers, EarlyCDT-Lung test, lung cancer, prediagnostic samples, AUTOANTIBODY TEST, VALIDATION

ID: 325919529